Dyspepsia Market Research Report, by Diagnosis ( Blood Tests, Breath Tests, Stool Tests ), Treatment (Antacids, Antibiotics, H2 Blockers, Proton Pump Inhibitors), End-User (Hospital, Clinic, Ambulatory Surgical Centre) - Forecast Till 2030

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Dyspepsia Market, by Diagnosis

6.1 Introduction

6.2 Blood Tests

6.3 Breath Tests

6.4 Stool Tests

6.5 Endoscopy

6.6 X-ray

6.7 CT scan

6.8 Others

Chapter 7. Global Dyspepsia Market, by Treatment

7.1 Introduction

7.2 Antacids

7.2.1 Calcium Carbonate

7.2.2 Loperamide

7.2.3 Simethicone

7.2.4 Sodium Bicarbonate

7.2.5 Others

7.3 Antibiotics

7.3.1 Amoxicillin

7.3.2 Clarithromycin

7.3.3 Metronidazole

7.3.4 Others

7.4 H2 Blockers

7.4.1 Cimetidine

7.4.2 Famotidine

7.4.3 Nizatidine

7.4.4 Ranitidine

7.4.5 Others

7.5 Proton Pump Inhibitors (PPIs)

7.5.1 Esomeprazole

7.5.2 Lansoprazole

7.5.3 Omeprazole

7.6 Prokinetics

7.6.1 Bethanechol

7.6.2 Metoclopramide

7.7 Psychological Therapies

7.8 Others

Chapter 8. Global Dyspepsia Market, by End-User

8.1 Introduction

8.2 Hospitals and Clinics

8.3 Ambulatory Surgical Centers

8.4 Pharmacies

8.5 Diagnostic Centers

8.6 Others

Chapter 9. Global Dyspepsia Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 AstraZeneca

11.1.1 Company Overview

11.1.2 Type Overview

11.1.3 Financials

11.2.4 Key Developments

11.1.5 SWOT Analysis

11.2 GlaxoSmithKline

11.2.1 Company Overview

11.2.2 Type Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Takeda Pharmaceutical Company

11.3.1 Company Overview

11.3.2 Type Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Johnson & Johnson

11.4.1 Company Overview

11.4.2 Type/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Eisai Co., Ltd

11.5.1 Company Overview

11.5.2 Type Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Abbott Laboratories

11.6.1 Company Overview

11.6.2 Type Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 SALIX PHARMACEUTICALS

11.7.1 Overview

11.7.2 Type Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Bayer AG

11.8.1 Overview

11.8.2 Type Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Boehringer Ingelheim GmbH

11.9.1 Overview

11.9.2 Type Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Sanofi

11.10.1 Overview

11.10.2 Type Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 Allergan Plc

11.11.1 Overview

11.11.2 Type Overview

11.11.3 Financials

11.11.4 Key Developments

Chapter 12 Appendix

LIST OF TABLES

Table 1 Dyspepsia Market Industry Synopsis, 2020–2027

Table 2 Global Dyspepsia Market Estimates & Forecast, 2020–2027, (USD Million)

Table 3 Global Dyspepsia Market, by Region, 2020–2027, (USD Million)

Table 4 Global Dyspepsia Market, by Diagnosis, 2020–2027, (USD Million)

Table 5 Global Dyspepsia Market, by Treatment, 2020–2027, (USD Million)

Table6 Global Dyspepsia Market, by End-User, 2020–2027, (USD Million

Table7 North America: Dyspepsia Market, by Diagnosis, 2020–2027, (USD Million)

Table 8 North America: Dyspepsia Market, by Treatment, 2020–2027, (USD Million)

Table 9 North America: Dyspepsia Market, by End-User, 2020–2027, (USD Million)

Table 10 US: Dyspepsia Market, by Diagnosis, 2020–2027, (USD Million)

Table 11 US: Dyspepsia Market, by Treatment, 2020–2027, (USD Million)

Table 12 US: Dyspepsia Market, by End-User, 2020–2027, (USD Million)

Table 13 Canada: Dyspepsia Market, by Diagnosis, 2020–2027, (USD Million)

Table 14 Canada: Dyspepsia Market, by Treatment, 2020–2027, (USD Million)

Table 15 Canada: Dyspepsia Market, by End-User, 2020–2027, (USD Million)

Table 16 South America: Dyspepsia Market, by Diagnosis, 2020–2027, (USD Million)

Table 17 South America: Dyspepsia Market, by Treatment, 2020–2027, (USD Million)

Table 18 South America: Dyspepsia Market, by End-User, 2020–2027, (USD Million)

Table 19 Europe: Dyspepsia Market, Diagnosis, 2020–2027, (USD Million)

Table 20 Europe: Dyspepsia Market, Type, 2020–2027, (USD Million)

Table 21 Europe: Dyspepsia Market, Technology, 2020–2027, (USD Million)

Table 32 Europe: Dyspepsia Market, by Treatment, 2020–2027, (USD Million)

Table 23 Europe: Dyspepsia Market, by End-User, 2020–2027, (USD Million)

Table 24 Western Europe: Dyspepsia Market, by Diagnosis, 2020–2027, (USD Million)

Table 25 Western Europe: Dyspepsia Market, by Treatment, 2020–2027, (USD Million)

Table 26 Western Europe: Dyspepsia Market, by End-User, 2020–2027, (USD Million)

Table 27 Eastern Europe: Dyspepsia Market, by Diagnosis, 2020–2027, (USD Million)

Table 28 Eastern Europe: Dyspepsia Market, by Treatment, 2020–2027, (USD Million)

Table 29 Eastern Europe: Dyspepsia Market, by End-User, 2020–2027, (USD Million)

Table 30 Asia-Pacific: Dyspepsia Market, by Diagnosis, 2020–2027, (USD Million)

Table 31 Asia-Pacific: Dyspepsia Market, by Treatment, 2020–2027, (USD Million)

Table 32 Asia-Pacific: Dyspepsia Market, by End-User, 2020–2027, (USD Million)

Table 33 Middle East & Africa: Dyspepsia Market, by Diagnosis, 2020–2027, (USD Million)

Table 34 Middle East & Africa: Dyspepsia Market, by Treatment, 2020–2027, (USD Million)

Table 35 Middle East & Africa: Dyspepsia Market, by End-User, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Dyspepsia Market

Figure 3 Market Dynamics for Global Dyspepsia Market

Figure 4 Global Dyspepsia Market Share, by Diagnosis 2020

Figure 5 Global Dyspepsia Market Share, by Treatment 2020

Figure 6 Global Dyspepsia Market Share, by End-User, 2020

Figure 7 Global Dyspepsia Market Share, by Region, 2020

Figure 8 North America Dyspepsia Market Share, by Country, 2020

Figure 9 Europe Dyspepsia Market Share, by Country, 2020

Figure 10 Asia-Pacific Dyspepsia Market Share, by Country, 2020

Figure 11 Middle East & Africa Dyspepsia Market Share, by Country, 2020

Figure 12 Global Dyspepsia Market: Company Share Analysis, 2020 (%)

Figure 13 AstraZeneca: Key Financials

Figure 14 AstraZeneca: Segmental Revenue

Figure 15 AstraZeneca: Geographical Revenue

Figure 16 GlaxoSmithKline: Key Financials

Figure 17 GlaxoSmithKline: Segmental Revenue

Figure 18 GlaxoSmithKline: Geographical Revenue

Figure 19 Takeda Pharmaceutical Company : Key Financials

Figure 20 Takeda Pharmaceutical Company : Segmental Revenue

Figure 21 Takeda Pharmaceutical Company : Geographical Revenue

Figure 22 Johnson & Johnson : Key Financials

Figure 23 Johnson & Johnson : Segmental Revenue

Figure 24 Johnson & Johnson : Geographical Revenue

Figure 25 Abbott Laboratories : Key Financials

Figure 26 Abbott Laboratories : Segmental Revenue

Figure 27 Abbott Laboratories : Geographical Revenue

Figure 28 Eisai Co., Ltd : Key Financials

Figure 29 Eisai Co., Ltd : Segmental Revenue

Figure 30 Eisai Co., Ltd : Geographical Revenue

Figure 31 SALIX PHARMACEUTICALS : Key Financials

Figure 32 SALIX PHARMACEUTICALS : Segmental Revenue

Figure 33 SALIX PHARMACEUTICALS : Geographical Revenue

Figure 34 Bayer AG: Key Financials

Figure 35 Bayer AG: Segmental Revenue

Figure 36 Bayer AG: Geographical Revenue

Figure 37 Boehringer Ingelheim GmbH : Key Financials

Figure 38 Boehringer Ingelheim GmbH : Segmental Revenue

Figure 39 Boehringer Ingelheim GmbH : Geographical Revenue

Figure 40 Sanofi: Key Financials

Figure 41 Sanofi: Segmental Revenue

Figure 42 Sanofi: Geographical Revenue

Figure 43 Allergan Plc: Key Financials

Figure 44 Allergan Plc: Segmental Revenue

Figure 45 Allergan Plc: Geographical Revenue